Oryzon Genomics S.A. ORYZF
3.10 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
3.45 Day range 3.45
3.10 52-week range 3.70
- YTD
- -7.81%
- 1 year
- -14.20%
- Market cap
- 253.86M
- EPS (ttm)
- -0.03
- YTD return
- -7.81%
- 1-year return
- -14.20%
- Volume
- 100
- Avg volume
- 709
- Open
- 3.45
- Previous close
- 3.10
- Day's range
- 3.45 – 3.45
- 52-week range
- 3.10 – 3.70
2Y +1.17 (+60.62%)
News
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors 
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting 
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease 
ORYZON to Participate in Upcoming Events in November 
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder 
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
Your note
Sign in to keep a note on ORYZF — it syncs with the Stock Master app.